Rilonacept: Uses, Side Effects, and Mechanism of Action

Rilonacept is an injectable biologic drug that works by trapping inflammatory signaling molecules called interleukin-1 alpha and interleukin-1 beta before they can trigger immune responses in the body. It carries two FDA approvals: one granted in 2008 for cryopyrin-associated periodic syndromes (CAPS), a group of rare inherited inflammatory conditions, and another for recurrent pericarditis, a painful and often debilitating inflammation of the sac surrounding the heart. The drug’s mechanism and clinical profile are worth understanding in some detail, because rilonacept occupies a distinctive niche among anti-inflammatory biologics.

How Rilonacept Works

The body uses interleukin-1 (IL-1) as a key alarm signal during inflammation. When cells detect tissue damage or infection, they release IL-1 alpha and IL-1 beta, which in turn recruit immune cells, trigger fever, and ramp up production of other inflammatory molecules like IL-6 and C-reactive protein (CRP). In healthy people, these cascades are temporary and self-limiting. In diseases driven by IL-1 overproduction, the alarm never shuts off, and the resulting chronic inflammation damages tissues over months or years.

Rilonacept is engineered as a “cytokine trap.” It is a large fusion protein that mimics the parts of the IL-1 receptor that IL-1 normally binds to, fused to a portion of a human antibody. When injected, it circulates in the bloodstream and binds to IL-1 alpha and IL-1 beta before those molecules can reach their actual receptors on cells.¹ By intercepting the signal, rilonacept blocks the downstream cascade of inflammation. It also binds a related molecule called IL-1 receptor antagonist, though this binding is considered less clinically relevant because the antagonist is itself an anti-inflammatory signal.

Once injected under the skin, rilonacept is absorbed slowly, reaching peak blood levels in roughly three days. Its half-life in adults is about a week, which is why it is dosed once weekly rather than daily.² That weekly dosing schedule is a practical advantage over some other IL-1 blockers that require daily injections.³

Cryopyrin-Associated Periodic Syndromes

Rilonacept’s first FDA approval, in February 2008, was for treating two forms of CAPS: familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). These are rare genetic conditions in which mutations cause the immune system to produce excessive IL-1, leading to recurring episodes of fever, rash, joint pain, and fatigue. CAPS was granted orphan drug status because it affects a very small number of people, and rilonacept was the first therapy approved specifically for it.⁴ The approval covered adults and children aged 12 and older.

Clinical trials demonstrated that rilonacept substantially reduced symptoms in CAPS patients. In two sequential placebo-controlled studies, treatment improved all measured outcomes, including the number of days patients experienced multi-symptom flares, individual symptom scores, patient and physician assessments of disease activity, and limitations in daily activities. Blood markers of inflammation, CRP and serum amyloid A (SAA), also dropped significantly.⁵

Longer-term follow-up reinforced those results. In an open-label extension study lasting 72 to 96 weeks, the mean key symptom score dropped from 2.6 at baseline to zero, and the proportion of days patients spent having multi-symptom flares fell from about 35% to under 3%. Inflammatory markers that had been elevated at baseline normalized and stayed that way.⁶ For people living with a condition that can smolder for years, that sustained suppression of flares is meaningful.

Recurrent Pericarditis

Recurrent pericarditis is far more common than CAPS, and it became rilonacept’s second approved indication. Pericarditis is inflammation of the pericardium, the thin sac enclosing the heart. A first episode usually resolves with anti-inflammatory medications like colchicine or NSAIDs, but roughly a third of patients go on to have recurrences, sometimes many. Recurrent episodes cause severe chest pain, limit activity, and can lead to hospitalizations. For patients who keep relapsing despite standard treatment, the options historically were limited and often involved long-term corticosteroid use with all its attendant side effects.

The pivotal evidence came from the RHAPSODY trial, a phase 3 study published in the New England Journal of Medicine. Patients with active recurrent pericarditis were first treated with rilonacept in an open-label run-in period, then those who responded were randomly assigned to continue rilonacept or switch to placebo. The results were striking: only 2 of 30 patients (7%) in the rilonacept group experienced a recurrence during the withdrawal period, compared with 23 of 31 patients (74%) in the placebo group. The difference was so large that the median time to recurrence could not even be calculated for the rilonacept group because too few events occurred.⁷ An imaging substudy from the same trial confirmed the pattern: none of the patients receiving rilonacept had a recurrence, compared with about 71% of those on placebo.⁸

A phase 2 trial had earlier shown that the benefit appears quickly. In symptomatic patients, pain scores on a numeric rating scale dropped from 4.5 at baseline to 0.7, and CRP fell from 4.62 mg/dL to 0.38 mg/dL by the end of the treatment period. Researchers described the response as rapid, with improvements observed after the very first dose.⁹ For someone in the middle of a painful flare, the speed of relief matters as much as the overall recurrence statistics.

Quality of Life on Treatment

Clinical trial endpoints like recurrence rates and CRP levels tell part of the story, but they do not capture what it feels like to live with or without a disease. The RHAPSODY trial also collected patient-reported outcomes measuring health-related quality of life, sleep quality, pain, and overall symptom severity. All of those measures improved significantly during rilonacept treatment. Patients who continued on rilonacept during the randomized withdrawal period maintained those improvements, while those switched to placebo who then experienced a recurrence saw their quality-of-life scores deteriorate, only to improve again after they were given rescue rilonacept.¹⁰

Sleep disruption in particular is an underappreciated burden for people with recurrent pericarditis. Chest pain often worsens when lying flat, and the anxiety of unpredictable flares compounds the problem. The documented sleep improvement on rilonacept suggests the drug addresses more than just the inflammatory biology; it gives patients their nights back, which cascades into daytime functioning and emotional well-being.

Side Effects and Safety Profile

The most frequently reported adverse effects across trials are upper respiratory tract infections and injection-site reactions.¹¹ Injection-site reactions, which can include redness, swelling, or mild pain at the site of the subcutaneous shot, are common with many injectable biologics and tend to be mild. Upper respiratory infections make sense mechanically: IL-1 is part of the body’s early defense against pathogens, so blocking it reduces the immune system’s first line of response to ordinary viruses.

The infection risk extends beyond colds. Because rilonacept suppresses part of the immune system, there is a theoretical and observed increase in susceptibility to infections. Patients are typically advised not to start treatment during an active infection, and clinicians watch for signs of serious infections during therapy. Live vaccines are generally avoided while on rilonacept, because a blunted immune response could allow a live-attenuated virus to cause actual disease rather than merely training the immune system.

Long-term safety data from the CAPS extension studies covering 72 to 96 weeks showed that tolerability remained favorable over time, with adverse reactions described as mostly mild to moderate.⁶ Serious adverse events were uncommon, and no new safety signals emerged with prolonged use. That said, the total number of patients studied is relatively small given that CAPS is rare and recurrent pericarditis trials enrolled modest populations. Post-marketing surveillance remains important for catching rare events that clinical trials are underpowered to detect.

Use in Children and Rare Genetic Conditions

The FDA approval for CAPS covers patients aged 12 and older, but rilonacept has also been studied in younger children, particularly those with deficiency of the IL-1 receptor antagonist (DIRA), a severe autoinflammatory condition that causes painful skin and bone inflammation starting in infancy. In an open-label pilot study, six children aged 3 to 6 with DIRA who had been maintained on daily anakinra injections were transitioned to weekly rilonacept. Five of the six required a dose increase to control micropustules, but after adjustment, all six achieved and maintained inflammatory remission for the entire 24-month study period. Growth remained normal, and quality of life improved, likely due in part to the relief of switching from daily to weekly injections. No serious adverse events were reported.¹²

Pharmacokinetic studies in children with systemic juvenile idiopathic arthritis have helped establish how the drug behaves in younger patients, where body size and metabolism differ from adults. The median half-life was about 9 days in this pediatric population, broadly consistent with the adult data, though there was wide variability from patient to patient.¹³ That variability means pediatric dosing sometimes requires individual adjustment rather than a one-size-fits-all approach.

Investigational Uses That Did Not Pan Out

Not every condition driven by IL-1 has turned out to be a winner for rilonacept. Gout, which involves IL-1-mediated inflammation around uric acid crystals in joints, was a logical target. A phase 3 trial tested rilonacept for preventing gout flares during the initiation of urate-lowering therapy, the period when flares are most likely. The drug did reduce flares: over 16 weeks, about 17-19% of patients on rilonacept experienced at least one flare compared with nearly 47% on placebo.¹⁴ However, when rilonacept was tested for treating acute gout attacks (the painful flares themselves), it did not significantly outperform indomethacin, a standard anti-inflammatory. Pain reduction over 72 hours with rilonacept alone was less than with indomethacin, and combining the two drugs did not produce a statistically meaningful additional benefit.¹⁵ Given that cheap, effective options already exist for acute gout, rilonacept did not earn regulatory approval for this use.

Atherosclerosis, the buildup of inflammatory plaques in arteries, has also been explored as a potential target. IL-1 drives leukocyte accumulation on blood vessel walls and stimulates production of CRP, both central to the inflammatory component of heart disease. A small phase 1/2 trial examined whether rilonacept could improve endothelial function and reduce CRP in patients with coronary artery disease. The rationale was sound, but the field has since moved toward larger trials with different IL-1-targeting drugs, and rilonacept has not advanced for this indication.

Practical Matters for Patients

Rilonacept is marketed under the brand name Arcalyst. It comes as a powder that must be reconstituted with sterile water before injection. Once mixed, the solution is injected subcutaneously, typically into the thigh or abdomen. Patients or caregivers can be trained to do this at home, avoiding the need for clinic visits for each dose. The once-weekly schedule is more manageable than the daily injections required by anakinra, the other widely used IL-1 blocker, and this is often cited as a meaningful quality-of-life advantage for patients on long-term treatment.³

For recurrent pericarditis, treatment typically begins with a loading dose (a larger first injection to build up drug levels quickly) followed by weekly maintenance doses. The loading dose is generally twice the maintenance dose. Your prescribing physician determines the exact regimen based on body weight and clinical situation. In CAPS, dosing follows a similar loading-then-maintenance pattern.

The drug must be refrigerated before reconstitution, and the reconstituted solution should be used promptly. These handling requirements are standard for biologic medications but are worth noting for patients who travel or have limited refrigeration access. Your treatment team should walk you through storage and preparation steps before you begin self-injection at home.

How Long Patients Stay on Treatment

One of the open questions for patients with recurrent pericarditis is how long they need to keep taking rilonacept. The RHAPSODY trial demonstrated that stopping the drug led to recurrence in most patients switched to placebo, suggesting that at least some patients need ongoing treatment. A follow-up analysis of long-term data from RHAPSODY confirmed sustained reduction in recurrence risk with continued use.¹⁶ In clinical practice, many specialists try tapering the dose or extending the interval between injections after a period of sustained remission, though there is no consensus protocol for when and how to taper.

For CAPS, treatment is typically lifelong because the underlying genetic mutation continues to drive IL-1 overproduction regardless of how well symptoms are controlled. Stopping the drug means the inflammatory cascade restarts. The long-term safety data spanning nearly two years of continuous use in extension studies are reassuring on that front, but patients understandably want to know what decades of use might look like. Data on truly long-term use spanning ten or twenty years are still accumulating.

Cost and Access

Rilonacept is an expensive biologic. As an orphan drug initially developed for a rare disease, it carries a high price tag. The introduction of a second, more common indication in recurrent pericarditis broadened the patient population but has not eliminated affordability concerns. Insurance coverage varies, and prior authorization is commonly required. Patient assistance programs exist through the manufacturer, but navigating the financial side of biologic therapy remains a real burden for many patients and families. If your physician recommends rilonacept, it is worth asking the clinic’s pharmacy team about coverage and assistance options early in the process, before the first dose, rather than scrambling after treatment has started.

How Rilonacept Fits Among IL-1 Blockers

Rilonacept is not the only drug that targets IL-1. Anakinra, a recombinant form of the natural IL-1 receptor antagonist, was the first IL-1 blocker on the market and requires daily subcutaneous injections. Canakinumab is a monoclonal antibody that specifically targets IL-1 beta and is given as a monthly injection. Each has its own set of approved indications and trade-offs.

Rilonacept’s distinctive feature is its mechanism as a soluble decoy receptor, or “trap,” that captures both IL-1 alpha and IL-1 beta. Anakinra blocks the IL-1 receptor on cells (preventing both alpha and beta from binding), while canakinumab neutralizes only IL-1 beta. Whether capturing both forms of IL-1 in the bloodstream versus blocking the receptor on cells produces meaningfully different clinical outcomes is still debated; in practice, all three drugs are effective at controlling IL-1-driven inflammation. The choice often comes down to dosing convenience, cost, approved indication for the specific condition, and individual patient response. Rilonacept’s weekly dosing sits between anakinra’s daily schedule and canakinumab’s monthly schedule, offering a middle ground that balances convenience with flexibility to adjust doses when needed.

For recurrent pericarditis specifically, rilonacept is the only IL-1 blocker with a dedicated phase 3 trial and FDA approval, giving it the strongest regulatory backing for that condition. Anakinra has evidence from smaller studies and real-world experience, and canakinumab has been studied in related cardiac inflammation, but neither has matched the RHAPSODY trial’s rigor for pericarditis.